- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04599829
Assessment of the Safety and Performance of Ankle Ligament Supports in the Context of a Return to Sport After Sprain
Decathlon has developed Ankle STRONG products which are medical devices that must be positioned around the ankle to limit ankle sprain occurrence.
The Ankle STRONG devices cover a range of 3 products (Ankle STRONG 100/500/900). The differences between the devices is based on the strength of compression and the ankle maintain.
The objective of this multicentre study is to collect data on the related clinical complications and clinical outcomes of market-approved Decathlon Ankle STRONG products to demonstrate safety and performance of these devices in a real-world setting.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59000
- Centre Hospitalier Universitaire de Lille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is aged ≥ 18 years old
- Subject has a recent mild OR moderate OR serious ankle sprain
- The current condition of his/her ankle allows the subject to resume usual physical activity
- Subject has been informed and is willing to sign an informed consent form
- Subject is willing to comply with protocol requirements and return to the study center for all clinical evaluations and required follow-up (12 weeks)
- Subject is affiliated to the French social security regime
Non-inclusion Criteria:
- Subject has conditions that may interfere with his/her ability to understand protocol requirements, participate in scheduled visits, or provide his/her informed consent
- Subject has worn a support (ankle brace or articulated orthosis) since his/her recent injury
- Subject has resumed regular physical activity since his/her recent injury
- Subject has any medical condition that could impact the study at investigator's discretion
- Subject has a known hypersensitivity or allergy to the components of the device (polyamide, elastane, polyester, cotton)
- Adult subject to legal protection measure
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Orthosis Group 1
Use of AnkleSTRONG100 device
|
At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included.
Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
|
Control Group 1
Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
|
|
Orthosis Group 2
Use of AnkleSTRONG500 device
|
At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included.
Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
|
Control Group 2
Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
|
|
Orthosis Group 3
Use of AnkleSTRONG900 device
|
At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included.
Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
|
Control Group 3
Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional score
Time Frame: 12 weeks of follow-up
|
Comparison of the functional result (Karlsson Ankle Function Score, 0-100 points) between the baseline and last follow-up visit in each group (orthosis vs control), for each device model
|
12 weeks of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (adverse events)
Time Frame: 12 weeks of follow-up
|
Comparison of adverse events rates between the groups (orthosis vs control), for each device model
|
12 weeks of follow-up
|
Confidence level
Time Frame: At baseline and 12 weeks of follow-up
|
Gap in the confidence level (patient rated outcome with 6 questions, ranging from 0 to 100) related to physical activity, between the baseline and last follow-up visit in each group (orthosis vs control), for each device model
|
At baseline and 12 weeks of follow-up
|
Ankle instability
Time Frame: At 4 weeks, 8 weeks and 12 weeks of follow-up
|
Comparison of ankle instability, assessed through a numerical rating scale (NRS, ranging from 0 to 10), between the groups (orthosis vs control), for each device model
|
At 4 weeks, 8 weeks and 12 weeks of follow-up
|
Ankle pain
Time Frame: At 4 weeks, 8 weeks and 12 weeks of follow-up
|
Comparison of ankle pain, assessed through NRS (ranging from 0 to 10), between the groups (orthosis vs control), for each device model
|
At 4 weeks, 8 weeks and 12 weeks of follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Valérie WIECZOREK, Centre Hospitalier Universitaire de Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ankleSTRONG100-500-900
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankle Sprain 1St Degree
-
Instituto Mexicano del Seguro SocialCompletedAnkle Sprain | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeMexico
-
Université Catholique de LouvainCompletedAnkle Sprain 1St Degree | Ankle Sprain 2Nd DegreeBelgium
-
Vanderbilt University Medical CenterRecruitingMusculoskeletal Injury | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeUnited States
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
University of VirginiaNational Athletic Training Association Research & Education FoundationUnknownLateral Ankle SprainUnited States
-
Hospital Universitario Infanta LeonorCompletedMild Ankle SprainSpain
-
University Hospital, GrenobleCompleted
-
Université Catholique de LouvainUZ Leuven, campus Pellenberg (Belgium)RecruitingChronic Ankle Instability | Lateral Ankle SprainBelgium
-
Walter van der WeegenGelre Hospitals; Medinova ClinicsRecruitingAnkle Sprains | Talofibular; Sprain (Strain)Netherlands
Clinical Trials on AnkleSTRONG100/500/900
-
Berkeley Eye CenterCompleted
-
Haag-Streit AGAravind Eye Hospitals, IndiaNot yet recruiting
-
Haag-Streit AGUniversity Hospital, Basel, SwitzerlandCompletedOptical Biometry of the Human Eye | General Analysis of the Anterior Chamber of the Human EyeSwitzerland
-
Haag-Streit AGUniversity Hospital, Basel, SwitzerlandCompletedOptical Biometry of the Human Eye | General Analysis of the Anterior Chamber of the Human EyeSwitzerland
-
University Hospital TuebingenHaag-Streit AGCompleted
-
Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.CompletedHealthyUnited Kingdom
-
McMaster UniversityWithdrawn
-
Seoul National University HospitalCompletedNeurogenic Bladder | Detrusor Overactivity | Detrusor UnderactivityKorea, Republic of
-
McGill UniversityRecruitingHeart Failure | Chronic Obstructive Pulmonary Disease | Interstitial Lung DiseaseCanada
-
McGill UniversityRecruitingHeart Failure | Chronic Obstructive Pulmonary Disease | Interstitial Lung DiseaseCanada